A Phase 2 Study of the JAK1/JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High-Risk CRLF2-Rearranged and/or JAK Pathway-Mutant Acute Lymphoblastic Leukemia
Conditions
Lymphoid Leukemia
Phase II
Volunteers
Health Professionals
What is the purpose of this trial?
This is a nonrandomized study of ruxolitinib in combination with a standard multi-agent chemotherapy regimen for the treatment of B-cell acute lymphoblastic leukemia. Part 1 of the study will optimize the dose of study drug (ruxolitinib) in combination with the chemotherapy regimen. Part 2 will evaluate the efficacy of combination chemotherapy and ruxolitinib at the recommended dose determined in Part 1.
- Trial withIncyte Corporation
- Start Date06/08/2020
- End Date02/01/2024
I'm interested in volunteering
If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8343
Sub-Investigators
- Amer Zeidan, MBBS
- Aron Flagg, MD
- Asher Marks, MD
- Claudia Auerbach, APRN
- Erin Medoff
- Farzana Pashankar, MD, MRCP
- Juan Vasquez, MD
- Julie Baker
- Mary Jane Hogan, MD, MPH, FAAP
- Nikolai Podoltsev, MD, PhD
- Prasanna Ananth, MD, MPH
- Rebecca Cheron, APRN
- Rozalyn Rodwin, MD
- Stephanie Halene, MD, PhD
- Stephanie Massaro, MD, MPH
- Stephanie Prozora, MD
- Thomas Prebet, MD, PhD
- Last Updated07/15/2021
- Study HIC#1606018018